Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

ABSTRACT:

SUBMITTER: Keating C 

PROVIDER: S-EPMC12184100 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature